Fig. 7.

TRIM21 suppressed hepatic glucose and lipid metabolic disorders by regulating PEPCK1 and FASN expression. a–d C57BL/6J mice fed HFD for 12 weeks were injected with Ad-TRIM21, Ad-PEPCK1, and/or Ad-FASN via tail vein injection. Seven days after injection, GTT (a), ITT (b), liver TG (c), and serum TG (d) were measured as indicated. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. Ad-GFP group. n = 7 mice for each group. e Mouse primary hepatocytes were co-infected with Ad-TRIM21, Ad-PEPCK1, and/or Ad-FASN for 24 h, then treated with palmitic acid (0.25 mM) and oleic acid (0.5 mM) for another 24 h. Intracellular TG levels were measured. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. Ad-GFP group. n = 6 per group. f Mouse primary hepatocytes were infected with Ad-GFP or Ad-TRIM21 for 24 h before being treated with/without palmitic acid (0.25 mM) for 16 h. Before collection, the cells were incubated with 100 nmol/L insulin for 20 min to stimulate insulin signaling. β-Actin was used as the loading control. Quantification data was shown in the lower panel. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. control group. n = 3 per group